Vertebrobasilar thrombolysis with intravenous tirofiban: Case report

The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolys...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2002-04, Vol.13 (2), p.81-84
Main Authors: LIEBESKIND, David S, POLLARD, John R, SCHWARTZ, Eric D, CUCCHIARA, Brett L, MCGARVEY, Michael L, HURST, Robert W
Format: Article
Language:English
Subjects:
Aged
Arterial Occlusive Diseases - complications
Arterial Occlusive Diseases - drug therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Stroke - complications
Stroke - drug therapy
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
Treatment Outcome
Tyrosine - administration & dosage
Tyrosine - adverse effects
Tyrosine - analogs & derivatives
Vertebrobasilar Insufficiency - complications
Vertebrobasilar Insufficiency - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.
ISSN:0929-5305
1573-742X
DOI:10.1023/A:1016242713327